Skip to main content
Yuyu Pharma, Inc. logo

Yuyu Pharma, Inc. — Investor Relations & Filings

Ticker · 000220 ISIN · KR7000220004 KO Manufacturing
Open in API
Filings indexed 303 across all filing types
Latest filing 2025-03-19 Audit Report / Informat…
Country KR South Korea
Listing KO 000220

About Yuyu Pharma, Inc.

https://www.yuyu.co.kr/

Yuyu Pharma, Inc., established in 1941, is a healthcare company focused on the development, manufacturing, and marketing of pharmaceutical products. The company is committed to creating innovative therapeutics to address healthcare challenges and improve quality of life. Its research and development efforts are concentrated on key therapeutic areas, with a notable emphasis on treatments for central nervous system disorders, including Alzheimer's disease. The company operates through several divisions, including Yuyu Healthcare, which provides pharmaceutical-standard Original Design Manufacturer (ODM) and Original Equipment Manufacturer (OEM) services.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing from Yuyu Pharma titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, profit/loss), and confirms the receipt of the audit report from the external auditor (Shinwoo Accounting Corp). While it contains financial data, it is a standard regulatory disclosure of the audit results rather than the full annual report (10-K) or a standalone audit report document (AR). In the context of Korean regulatory filings (DART/KIND), this is classified as a report publication/submission announcement regarding the audit results. FY 2024
2025-03-19 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Yuyu Pharmaceutical, covering the fiscal year 2024. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. This aligns perfectly with the definition of an Audit Report (AR), which covers standalone audit reports and applied accounting principles. FY 2024
2025-03-19 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under Article 147 of the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (stock-backed loans) of major shareholders and their special relations. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-03-11 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Yuyu Pharmaceutical. It contains the meeting agenda, details on voting procedures (including electronic voting), director information, and financial statements (balance sheet and income statement) for the 85th fiscal year. While it contains financial data, it is primarily a proxy solicitation document sent to shareholders to inform them of the upcoming meeting and request their votes on specific agenda items (e.g., approval of financial statements, election of directors). Therefore, it is classified as a Proxy Solicitation & Information Statement.
2025-03-10 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with other companies' meetings. This is a specific regulatory disclosure requirement in the Korean market and does not fit into the categories of AGM materials, proxy statements, or reports themselves, but rather serves as a regulatory notification. Therefore, it is classified as a Regulatory Filing (RNS).
2025-03-10 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is an official announcement from Yuyu Pharma regarding the decision to pay cash dividends. It specifies the dividend amount per share, the dividend yield, the total dividend amount, the record date, and the date of the upcoming general meeting of shareholders. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2025-02-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.